Pulse 2.0

Roivant Reports 56.3% Placebo-Adjusted PVR Reduction In Phase 2 Mosliciguat PH-ILD Study, Starts Phase 3 PHrontier Trial

Roivant Sciences announced positive results from the Phase 2 PHocus study of mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease, or PH-ILD, with the study ...
Healio

Study: Statin use halves risk for PVR after retinal detachment surgery

Please provide your email address to receive an email when new articles are posted on . Statin use reduced proliferative vitreoretinopathy risk by 47% and complex reoperation rate by 48%. All dosing ...
Medical Xpress

Preclinical tests show mRNA-based treatments effective for blinding condition

A preclinical study by Mass Eye and Ear investigators showed that a novel mRNA-based therapy may be able to prevent blindness and scarring from proliferative vitreoretinopathy (PVR) following a ...
ascopubs.org

Phase 1 study of NTX1088, a first-in-class anti-PVR monoclonal antibody, as monotherapy and combined with pembrolizumab, in patients with advanced solid malignancies.

Evaluation of the combination of regorafenib + avelumab in patients with HPV-associated cancer: The phase II REGOMUNE study. This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting I. This ...